Wockhardt, DBS agree to out-of-court settlement

Dispute over loan that the drug manufacturer had taken from the Singapore-based lender.

Debt-ridden pharmaceutical company and have agreed to an out-of-court settlement of a dispute over loans the drug manufacturer had taken from the Singapore-based lender.

According to sources, both parties have approached the with a consent decree.

Last month, DBS had filed a winding-up petition against Wockhardt in the Bombay High Court, seeking liquidation of the company in order to pay off dues to its creditors.

Under the consent decree, DBS Bank’s derivative exposure of Rs 91 crore in the drug maker has been settled at 75 per cent discount, sources said.

Further, the lender’s working capital exposure of Rs 44 crore has been settled at Rs 37 crore, sources added.

While a Wockhardt spokesperson could not be reached, a DBS spokesperson declined to comment on the issue, stating the matter is subjudice.

According to sources, the settlement deal is subject to approval from corporate debt restructuring (CDR) lenders.

Wockhardt, which has a debt of over Rs 3,700 crore, had undertaken a programme, which was approved by an empowered group on June 30, 2009, and 14 banks participated in it.

The company has sold some of its non-core business to pay off debt.

As part of the CDR process, the debt-ridden drug maker sold off its nutrition and animal healthcare business for about Rs 790 crore and completed the CDR much ahead of scheduled deadline of 2015.

Wockhardt also recently signed a Rs 909-crore deal with hospital chain Fortis Healthcare to sell its 10 hospitals.

The company’s promoters, the Khorakiwala family, recently sold its German subsidiary Esparma for Rs 120 crore.

image
Business Standard
177 22
Business Standard

Wockhardt, DBS agree to out-of-court settlement

Press Trust Of India  |  New Delhi 



Dispute over loan that the drug manufacturer had taken from the Singapore-based lender.

Debt-ridden pharmaceutical company and have agreed to an out-of-court settlement of a dispute over loans the drug manufacturer had taken from the Singapore-based lender.

According to sources, both parties have approached the with a consent decree.

Last month, DBS had filed a winding-up petition against Wockhardt in the Bombay High Court, seeking liquidation of the company in order to pay off dues to its creditors.

Under the consent decree, DBS Bank’s derivative exposure of Rs 91 crore in the drug maker has been settled at 75 per cent discount, sources said.

Further, the lender’s working capital exposure of Rs 44 crore has been settled at Rs 37 crore, sources added.

While a Wockhardt spokesperson could not be reached, a DBS spokesperson declined to comment on the issue, stating the matter is subjudice.

According to sources, the settlement deal is subject to approval from corporate debt restructuring (CDR) lenders.

Wockhardt, which has a debt of over Rs 3,700 crore, had undertaken a programme, which was approved by an empowered group on June 30, 2009, and 14 banks participated in it.

The company has sold some of its non-core business to pay off debt.

As part of the CDR process, the debt-ridden drug maker sold off its nutrition and animal healthcare business for about Rs 790 crore and completed the CDR much ahead of scheduled deadline of 2015.

Wockhardt also recently signed a Rs 909-crore deal with hospital chain Fortis Healthcare to sell its 10 hospitals.

The company’s promoters, the Khorakiwala family, recently sold its German subsidiary Esparma for Rs 120 crore.

RECOMMENDED FOR YOU

Wockhardt, DBS agree to out-of-court settlement

Dispute over loan that the drug manufacturer had taken from the Singapore-based lender.

Dispute over loan that the drug manufacturer had taken from the Singapore-based lender.

Debt-ridden pharmaceutical company and have agreed to an out-of-court settlement of a dispute over loans the drug manufacturer had taken from the Singapore-based lender.

According to sources, both parties have approached the with a consent decree.

Last month, DBS had filed a winding-up petition against Wockhardt in the Bombay High Court, seeking liquidation of the company in order to pay off dues to its creditors.

Under the consent decree, DBS Bank’s derivative exposure of Rs 91 crore in the drug maker has been settled at 75 per cent discount, sources said.

Further, the lender’s working capital exposure of Rs 44 crore has been settled at Rs 37 crore, sources added.

While a Wockhardt spokesperson could not be reached, a DBS spokesperson declined to comment on the issue, stating the matter is subjudice.

According to sources, the settlement deal is subject to approval from corporate debt restructuring (CDR) lenders.

Wockhardt, which has a debt of over Rs 3,700 crore, had undertaken a programme, which was approved by an empowered group on June 30, 2009, and 14 banks participated in it.

The company has sold some of its non-core business to pay off debt.

As part of the CDR process, the debt-ridden drug maker sold off its nutrition and animal healthcare business for about Rs 790 crore and completed the CDR much ahead of scheduled deadline of 2015.

Wockhardt also recently signed a Rs 909-crore deal with hospital chain Fortis Healthcare to sell its 10 hospitals.

The company’s promoters, the Khorakiwala family, recently sold its German subsidiary Esparma for Rs 120 crore.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard